RNA 针对小分子药物发现市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按适应症、最终用户、地区和竞争细分

全球 RNA 标靶小分子药物发现市场预计在预测期内将出现令人印象深刻的成长。这可以归因于癌症、遗传性疾病和病毒感染等疾病的日益普及以及製药和生物技术企业研发活动支出的增加。此外，主要市场参与者的不断增加、先进的医疗基础设施以及研发活动投资的增加预计将在预测期内创造利润丰厚的成长。同样，支持新疗法开发和商业化的日益完善的医疗保健系统也是多年来推动市场成长的主要因素。事实上，2020年，美国FDA核准了55种药物，其中超过65%是小分子治疗药物。值得注意的是，这些药物大多是传统上针对蛋白质而开发的。

RNA 相关疾病的盛行率不断增加

RNA 相关疾病的日益普及是全球 RNA 标靶小分子药物发现市场成长的关键驱动力之一。 RNA 在各种细胞过程中发挥关键作用，RNA 功能失调可导致各种疾病，包括癌症、遗传性疾病和病毒感染。这些疾病的盛行率不断增加，导致对 RNA 标靶小分子药物的需求不断增长。 RNA标靶小分子药物为治疗RNA相关疾病提供了一种有前景的方法。小分子可以选择性地结合特定的 RNA 标靶并调节其活性，为 RNA 失调引起的疾病提供潜在的治疗方法。例如，RNA标靶小分子药物在癌症治疗中显示出有希望的结果，特别是在传统化疗无效的情况下。它们还显示出治疗由 RNA 异常引起的遗传性疾病的潜力，例如囊性纤维化。 RNA 相关疾病的日益普及导致人们越来越关注 RNA 标靶小分子药物发现研究。许多製药公司、新创公司和研究机构都在这一领域进行了大量投资，这正在推动市场的成长。

市场概况
预测期	2024-2028
2022 年市场规模	110104万美元
2028 年市场规模	227669万美元
复合年增长率	12.98%
成长最快的细分市场	製药与生物技术公司
最大的市场	北美洲

RNA生物学的进展

RNA 生物学的进步在全球 RNA 靶向小分子药物发现市场的成长中发挥了重要作用。随着高通量定序和基因编辑等技术的进步，人们对 RNA 生物学的了解显着增加。这导致了新 RNA 标靶的鑑定和新型 RNA 标靶小分子药物的开发。 RNA 生物学的进步使研究人员能够更好地了解 RNA 分子导致疾病的机制。这种认识导致了以前未知或知之甚少的新 RNA 靶点的鑑定。新RNA标靶的发现为药物发现开闢了新的机会，促进了新型RNA标靶小分子药物的开发。此外，RNA 生物学的进步导致了用于 RNA 靶向小分子药物发现的新技术和工具的开发。例如，高通量筛选技术的进步使研究人员能够筛选大型化合物库，以快速识别潜在的 RNA 标靶药物。这加速了药物发现过程，并使新药的开发更有效。 RNA 生物学的进步也使得开发特异性和效力更高的 RNA 标靶小分子药物成为可能。透过了解 RNA 分子的结构和功能，研究人员可以设计选择性结合特定 RNA 标靶并调节其活性的小分子。

增加对 RNA 标靶药物发现研究的资助

RNA标靶药物发现研究资金的增加对全球RNA标靶小分子药物发现市场的成长产生了重大影响。 RNA靶向小分子药物为治疗各种疾病提供了一种有前途的方法，包括癌症、遗传性疾病和病毒感染。然而，开发这些药物是一个复杂的过程，需要大量的研发投资。增加对 RNA 标靶药物发现研究的资助有助于加速药物发现过程并提高成功的机会。资金可支持识别和验证 RNA 标靶、开发新筛选技术、设计小分子以及进行临床前和临床研究等方面的研究。此外，增加资金有助于吸引顶尖研究人员和科学家进入该领域，从而在 RNA 标靶药物发现研究方面带来更多创新和突破。资金的提供还可以鼓励学术界和工业界之间的合作，从而实现更有效率和有效的药物发现过程。包括政府、非营利组织和製药公司在内的一些组织正在大力投资 RNA 标靶药物发现研究。例如，美国国立卫生研究院 (NIH) 启动了多项旨在加速 RNA 标靶药物发现的倡议，包括以 RNA 为重点的加速药物合作伙伴关係和蓝图神经治疗网络。这些措施为该领域的研究人员提供了大量资金和资源。

对个人化医疗的需求不断增长

对个人化医疗不断增长的需求是全球 RNA 标靶小分子药物发现市场成长的重要驱动力。个人化医疗旨在根据每位患者的个别特征，考虑他们的基因组成、生活方式和环境，制定个人化的治疗方案。 RNA 标靶小分子药物为个人化医疗提供了一种有前途的方法，因为它们可以选择性地针对与患者疾病相关的特定 RNA 分子。 RNA标靶小分子药物可以针对个别患者的基因特征进行设计，从而实现更有效的治疗和更好的患者治疗结果。例如，癌症患者的 RNA 中可能存在特定突变，导致肿瘤生长。 RNA靶向小分子药物可以设计专门针对这种突变，从而实现更有效的治疗和更少的副作用。此外，RNA标靶小分子药物可用于治疗由特定RNA异常引起的罕见疾病。这些药物可以小批量开发和生产，使其成为个人化医疗的理想选择。个人化医疗需求不断增长是由多种因素推动的，包括基因组医学的进步、患者意识的提高和对更个性化护理的需求，以及开发和製造个人化疗法的技术的进步。许多製药公司和新创公司正在投资 RNA 标靶小分子药物发现研究，以满足日益增长的个人化医疗需求。这些公司正在利用 RNA 生物学、高通量筛选技术和计算方法的进步来开发个人化 RNA 标靶小分子药物。

近期发展

• In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic疾病.此次批准代表着 RNA 标靶药物发现领域的一个重要里程碑。
• 2020年，Alnylam Pharmaceuticals推出了美国FDA核准的首个RNA标靶小分子药物Lumasiran。 Lumasiran 适用于治疗第 1 型原发性高草酸尿症，这是一种罕见的遗传性疾病，可导致肾臟损伤和衰竭。
• 2019年，Alnylam Pharmaceuticals推出了Givosiran，一种RNA标靶小分子药物，用于治疗急性肝卟啉症。 Givosiran 的作用是靶向并降解 RNA，该 RNA 编码负责在患有这种罕见遗传疾病的患者中产生有毒血红素中间体的酶。
• 2021年，诺华推出了Inclisiran，一种用于治疗高胆固醇的RNA标靶小分子药物。 Inclisiran 会标靶并降解编码 PCSK9 的 RNA，PCSK9 是一种调节血液中胆固醇水平的蛋白质。

市场区隔

全球 RNA 标靶小分子药物发现市场可以按适应症、最终用户、区域和竞争格局进行细分。依适应症，市场可分为癌症、传染病、代谢性疾病、神经系统疾病等。根据最终用户，市场可以分为製药和生物製药公司、学术和研究机构、其他。

市场参与者

Accent Therapeutics.、Anima Biotech Inc.、Arrakis Therapeutics.、阿斯特捷利康.、Epics Therapeutics.、Expansion Therapeutics.、Hoffmann-La Roche Ltd.、H3 Biomedicine Inc.、PTC Therapeutics.、Ribometrix.、Servier Laboratories.Skyhawk Therapeutics、 Inc. 是全球 RNA 标靶小分子药物发现市场的一些领先参与者。

报告范围：

在本报告中，全球 RNA 标靶小分子药物发现市场除了详细介绍的产业趋势外，还分为以下几类：

RNA 标靶小分子药物发现市场，依适应症分类：

• 癌症
• 传染性疾病
• 代谢性疾病
• 神经系统疾病
• 其他

RNA 针对小分子药物发现市场，由最终用户提供：

• 製药和生物製药公司
• 学术及研究机构
• 其他的

RNA 标靶小分子药物发现市场（按地区）：

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
• 南美洲
  • 巴西
  • 阿根廷
  • 哥伦比亚
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

竞争格局

公司概况：对全球 RNA 靶向小分子药物发现市场主要公司的详细分析。

可用的客製化：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按地区（北美、欧洲、亚太地区、南美、中东和非洲）
  • 按公司划分 (2022)
• 市场地图
  • 按指示
  • 由最终用户
  • 按地区

第 6 章：北美 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲 RNA 标靶小分子药物发现市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（癌症、传染病、代谢性疾病、神经系统疾病、其他）
  • 最终用户（製药和生物製药公司、学术和研究机构、其他）
  • 按国家/地区
• MEA：国家分析
  • 南非 RNA 标靶小分子药物发现
  • 沙乌地阿拉伯 RNA 标靶小分子药物发现
  • 阿联酋 RNA 标靶小分子药物发现

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球 RNA 标靶小分子药物发现市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 财务（据报导）
• 主要人员
• SWOT分析
  • Accent Therapeutics.
  • Anima Biotech Inc.
  • Arrakis Therapeutics.
  • AstraZeneca Plc.
  • Epics Therapeutics.
  • Expansion Therapeutics.
  • F. Hoffmann-La Roche Ltd.
  • H3 Biomedicine Inc.
  • PTC Therapeutics.
  • Ribometrix.
  • Servier Laboratories.
  • Skyhawk Therapeutics, Inc.

第 16 章：策略建议

The Global RNA Targeting Small Molecule Drug Discovery Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing prevalence of diseases such as cancer, genetic disorders, and viral infections and rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. Also, the growing presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities are expected to create lucrative growth during the forecast period. Similarly, a growing well-established healthcare system that supports the development and commercialization of new therapies is also a major factor fuelling the growth of the market over the years. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. It is worth noting that majority of these drugs were conventionally developed to target proteins.

Increasing Prevalence of RNA-Related Diseases

The increasing prevalence of RNA-related diseases is one of the key drivers of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA plays a critical role in various cellular processes, and dysregulation of RNA function can lead to various diseases, including cancer, genetic disorders, and viral infections. The prevalence of these diseases is increasing, leading to a growing demand for RNA-targeted small molecule drugs. RNA-targeted small molecule drugs offer a promising approach for the treatment of RNA-related diseases. Small molecules can selectively bind to specific RNA targets and modulate their activity, offering a potential therapeutic approach for diseases caused by RNA dysregulation. For example, RNA-targeted small molecule drugs have shown promising results in the treatment of cancer, particularly in cases where traditional chemotherapy is not effective. They have also shown potential for the treatment of genetic disorders caused by RNA abnormalities, such as cystic fibrosis. The increasing prevalence of RNA-related diseases has led to an increased focus on RNA-targeted small molecule drug discovery research. Many pharmaceutical companies, startups, and research institutions are investing heavily in this area, which is driving the growth of the market.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 1101.04 Million
Market Size 2028	USD 2276.69 Million
CAGR (2023-2028)	12.98%
Fastest Growing Segment	Pharmaceutical & Biotechnology Companies
Largest Market	North America

Advancements in RNA Biology

Advancements in RNA biology have played a significant role in the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. With the advancement of technologies, including high-throughput sequencing and gene editing, the understanding of RNA biology has increased significantly. This has led to the identification of new RNA targets and the development of novel RNA-targeted small molecule drugs. Advancements in RNA biology have enabled researchers to better understand the mechanisms by which RNA molecules contribute to disease. This understanding has led to the identification of new RNA targets that were previously unknown or poorly understood. The discovery of new RNA targets has opened up new opportunities for drug discovery, leading to the development of novel RNA-targeted small molecule drugs. Furthermore, advancements in RNA biology have led to the development of new technologies and tools for RNA-targeted small molecule drug discovery. For example, advances in high-throughput screening technologies have enabled researchers to screen large libraries of compounds to identify potential RNA-targeted drugs quickly. This has accelerated the drug discovery process and enabled the development of new drugs more efficiently. Advancements in RNA biology have also enabled the development of RNA-targeted small molecule drugs with improved specificity and potency. By understanding the structure and function of RNA molecules, researchers can design small molecules that selectively bind to specific RNA targets and modulate their activity.

Increased Funding for RNA-Targeted Drug Discovery Research

Increased funding for RNA-targeted drug discovery research has a significant impact on the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA-targeted small molecule drugs offer a promising approach for the treatment of various diseases, including cancer, genetic disorders, and viral infections. However, developing these drugs is a complex process that requires significant investment in research and development. Increased funding for RNA-targeted drug discovery research can help to accelerate the drug discovery process and improve the chances of success. Funding can support research in identifying and validating RNA targets, developing new screening technologies, designing small molecules, and conducting preclinical and clinical studies. Furthermore, increased funding can help to attract top researchers and scientists to the field, leading to more innovation and breakthroughs in RNA-targeted drug discovery research. The availability of funding can also encourage collaborations between academia and industry, leading to more efficient and effective drug discovery processes. Several organizations, including governments, non-profit organizations, and pharmaceutical companies, are investing heavily in RNA-targeted drug discovery research. For example, the US National Institutes of Health (NIH) has launched several initiatives aimed at accelerating RNA-targeted drug discovery, including the RNA-focused Accelerating Medicines Partnership and the Blueprint Neurotherapeutics Network. These initiatives provide significant funding and resources for researchers working in the field.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, taking into account their genetic makeup, lifestyle, and environment. RNA-targeted small molecule drugs offer a promising approach for personalized medicine, as they can selectively target specific RNA molecules that are involved in a patient's disease. RNA-targeted small molecule drugs can be designed to be specific to individual patients' genetic profiles, leading to more effective treatments and better patient outcomes. For example, a patient with cancer may have a specific mutation in their RNA that is driving the growth of their tumor. RNA-targeted small molecule drugs can be designed to specifically target this mutation, leading to more effective treatment and fewer side effects. Furthermore, RNA-targeted small molecule drugs can be used to treat rare diseases caused by specific RNA abnormalities. These drugs can be developed and manufactured in small quantities, making them ideal for personalized medicine. The growing demand for personalized medicine is driven by several factors, including advances in genomic medicine, increasing patient awareness and demand for more personalized care, and improvements in technology for developing and manufacturing personalized therapies. Many pharmaceutical companies and startups are investing in RNA-targeted small molecule drug discovery research to meet the growing demand for personalized medicine. These companies are leveraging advancements in RNA biology, high-throughput screening technologies, and computational methods to develop personalized RNA-targeted small molecule drugs.

Rise in the Number of Startups and Small Companies Focusing on RNA-Targeted Drug Discovery

The rise in the number of startups and small companies focusing on RNA-targeted drug discovery is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Startups and small companies are playing a crucial role in advancing RNA-targeted drug discovery research and bringing innovative therapies to the market. Startups and small companies are often more agile and able to quickly adopt new technologies and approaches to drug discovery. These companies can focus on niche areas of RNA biology, allowing them to identify and develop RNA targets that may have been overlooked by larger pharmaceutical companies. Furthermore, startups and small companies are increasingly receiving funding and support from venture capitalists, government agencies, and non-profit organizations. This funding allows these companies to invest in research and development and advance their pipeline of RNA-targeted small molecule drugs. The rise of startups and small companies in the RNA-targeted drug discovery space is also leading to increased competition, which is driving innovation and improving the efficiency of the drug discovery process. This competition is also leading to the development of more affordable and accessible RNA-targeted small molecule drugs, which can benefit patients globally. Several startups and small companies focusing on RNA-targeted drug discovery have already made significant advances in the field. These companies have developed innovative screening platforms, identified novel RNA targets, and advanced promising RNA-targeted small molecule drugs into preclinical and clinical trials.

Recent Development

• In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic disease. This approval represents a significant milestone for the RNA-targeted drug discovery field.
• In 2020, Alnylam Pharmaceuticals launched Lumasiran, the first RNA-targeting small molecule drug approved by the US FDA. Lumasiran is indicated for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that can lead to kidney damage and failure.
• In 2019, Alnylam Pharmaceuticals launched Givosiran, an RNA-targeting small molecule drug for the treatment of acute hepatic porphyria. Givosiran works by targeting and degrading the RNA that encodes the enzyme responsible for producing toxic heme intermediates in patients with this rare genetic disease.
• In 2021, Novartis launched Inclisiran, an RNA-targeting small molecule drug for the treatment of high cholesterol. Inclisiran targets and degrades the RNA that encodes for PCSK9, a protein that regulates cholesterol levels in the blood.

Market Segmentation

Global RNA Targeting Small Molecule Drug Discovery market can be segmented by Indication, End Users, Region and Competitive Landscape. Based on the indication, the market can be segmented into Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others. Based on end users, the market can be differentiated into Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others.

Market Players

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc. are some of the leading players operating in the Global RNATargeting Small Molecule Drug Discovery Market.

Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication:

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Other

RNA Targeting Small Molecule Drug Discovery Market, By End Users:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Indication
  • 5.3.2. By End Users
  • 5.3.3. By Region

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End User

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End User

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End User
  • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End User

9. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End User

10. Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Accent Therapeutics.
  • 15.6.2 Anima Biotech Inc.
  • 15.6.3 Arrakis Therapeutics.
  • 15.6.4 AstraZeneca Plc.
  • 15.6.5 Epics Therapeutics.
  • 15.6.6 Expansion Therapeutics.
  • 15.6.7 F. Hoffmann-La Roche Ltd.
  • 15.6.8 H3 Biomedicine Inc.
  • 15.6.9 PTC Therapeutics.
  • 15.6.10 Ribometrix.
  • 15.6.11 Servier Laboratories.
  • 15.6.12 Skyhawk Therapeutics, Inc.

16. Strategic Recommendations